Inhibition of transforming growth factor beta/SMAD signal by MiR‐155 is involved in arsenic trioxide‐induced anti‐angiogenesis in prostate cancer

• Published in: Cancer science Vol. 105; no. 12; pp. 1541 - 1549
• Main Authors: Ji, Hui, Li, Yuan, Jiang, Fei, Wang, Xingxing, Zhang, Jianping, Shen, Jian, Yang, Xiaojun
• Format: Journal Article
• Language: English
• Published: England John Wiley & Sons, Inc 01.12.2014; Blackwell Publishing Ltd
• Subjects: 3' Untranslated regions; Acute promyeloid leukemia; Angiogenesis; Angiogenesis Inhibitors - pharmacology; Antineoplastic drugs; Antitumor agents; Apoptosis; Arsenic; Arsenic trioxide; Arsenicals - pharmacology; Cell growth; Cell Line, Tumor; Demethylation; Deoxyribonucleic acid; DNA; DNA methylation; DNA‐demethylation; Gene expression; Gene Expression Regulation, Neoplastic - drug effects; Human Umbilical Vein Endothelial Cells; Humans; Liver cancer; Male; Metastases; Metastasis; MicroRNAs - metabolism; microRNA‐155; miRNA; Molecular modelling; Original; Oxides - pharmacology; Promyeloid leukemia; Prostate cancer; Prostatic Neoplasms - metabolism; Prostatic Neoplasms - pathology; Secretion; Signal Transduction - drug effects; Smad protein; Smad Proteins - metabolism; Smad2 protein; Solid tumors; Studies; TGF‐β/SMAD signaling; Transforming Growth Factor beta - metabolism; Transforming growth factor-b; Tumors; Vascular endothelial growth factor; United States > US; China; Grand Island New York; microRNA-155; Angiogenesis; TGF-β/SMAD signaling; arsenic trioxide; DNA-demethylation
• ISSN: 1347-9032; 1349-7006
• DOI: 10.1111/cas.12548

Prostate cancer is the most common cause of cancer‐related deaths in men. Current practices for treatment of prostate cancer are less than satisfactory because of metastasis and recurrence, which are primarily attributed to angiogenesis. Hence, anti‐angiogenesis treatment is becoming a promising new approach for prostate cancer therapy. In addition to treating acute promyelocytic leukemia, arsenic trioxide (As2O3) suppresses other solid tumors, including prostate cancer. However, the effects of As2O3 on angiogenesis in prostate cancer cells, and the underlying molecular mechanisms remain unclear. In the present study, As2O3 attenuated angiogenic ability through microRNA‐155 (miR‐155)‐mediated inhibition of transforming growth factor beta (TGF‐β)/SMAD signal pathway in human prostate cancer PC‐3 and LNCaP cells in vitro and in vivo. Briefly, As2O3 inhibited the activations/expressions of both TGFβ‐induced and endogenous SMAD2/3. Furthermore, As2O3 improved the expression of miR‐155 via DNA‐demethylation. MiR‐155, which targeted the SMAD2‐3′UTR, decreased the expression and function of SMAD2. Knockdown of miR‐155 abolished the As2O3‐induced inhibitions of the TGF‐β/SMAD2 signaling, the vascular endothelial growth factor secretion and angiogenesis. Through understanding a novel mechanism whereby As2O3 inhibits angiogenic potential of prostate cancer cells, our study would help in the development of As2O3 as a potential chemopreventive agent when used alone or in combination with other current anticancer drugs. As2O3 improved the expression miR‐155 via DNA‐demethylation. As an up‐stream regulator of TGF‐β signaling, miR‐155 decreased the expression and function of SMAD2 by targeting the SMAD2‐3′UTR. Knockdown of miR‐155 abolished the As2O3‐induced inhibitions of the TGF‐β/SMAD2 signaling, the VEGF secretion, and the angiogenesis in prostate cancer cells in vitro and in vivo.